Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03463473 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study of MSB2311 in Advanced Solid Tumors
A Phase 1 study, sponsored by Suzhou Transcenta Therapeutics Co..
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT03463473: Completed Phase 1 study, sponsored by Suzhou Transcenta Therapeutics Co..
NCT03463473 is a Phase 1 study that has completed, run by Suzhou Transcenta Therapeutics Co.. The registered enrollment target is 42 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (30% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03463473, a Phase 1 study, has completed, sponsored by Suzhou Transcenta Therapeutics Co..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
This is a phase I study to determine the safety and toxicity, PK/PD, immunogenicity, biomarkers, anti-tumor activity and establish a preliminary recommended Phase 2 dose (RP2D) in subjects with advanced solid tumors.
Primary Outcome
Measured by number adverse events that are related to treatment
Interventions
- DRUG 3 mg/kg Q3W MSB2311 Injection
- DRUG 10 mg/kg Q3W MSB2311 Injection
- DRUG 20 mg/kg Q3W MSB2311 Injection
- DRUG 10 mg/kg Q2W MSB2311 Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2018-04-12 |
| Est. Completion | 2020-06-01 |
| Phase | Phase 1 |
What the finished NCT03463473 record still lists
NCT03463473 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (30% lower).
The record links to 0 conditions, and to 4 interventions - of which 3 mg/kg Q3W MSB2311 Injection is the first listed.
NCT03463473 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03463473 about?
NCT03463473 is a clinical study titled "A Phase I Study of MSB2311 in Advanced Solid Tumors". This is a phase I study to determine the safety and toxicity, PK/PD, immunogenicity, biomarkers, anti-tumor activity and establish a preliminary recommended Phase 2 dose (RP2D) in subjects with advanced solid tumors.
What is the current status of trial NCT03463473?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2018-04-12. Estimated completion is 2020-06-01.
What interventions are being tested in trial NCT03463473?
The interventions under investigation include: 3 mg/kg Q3W MSB2311 Injection (DRUG), 10 mg/kg Q3W MSB2311 Injection (DRUG), 20 mg/kg Q3W MSB2311 Injection (DRUG), 10 mg/kg Q2W MSB2311 Injection (DRUG).
Who is sponsoring clinical trial NCT03463473?
This trial is sponsored by Suzhou Transcenta Therapeutics Co., which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03463473's enrollment target sits among peer trials
42 1105th of 2000 higher than 876 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI